Clinical Trial Update: Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing nal-iri/lv5-fu versus paclitaxel as second-line therapy for metastatic esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• FLUOROURACIL (Fluorouracil)
• Leucovorin (folinic acid)
• Liposomal irinotecan (liposomal irinotecan)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED